# Kiromic BioPharma Inc. (KRBP)

Source: https://www.quantisnow.com/company/KRBP
Generated: 2026-11-22T17:15:07.892Z

- Ticker: KRBP
- Exchange: NASDAQ
- Sector: Health Care
- Industry:  Medicinal Chemicals and Botanical Products 
- IPO year: 2020
- Website: kiromic.com

## About

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

## Latest KRBP news and filings

- 2025-03-21 13:05 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-bankruptcy-or-receivership-5955508)
- 2025-03-17 21:26 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-other-events-5948005)
- 2025-02-19 21:57 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Kiromic BioPharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-kiromic-biopharma-inc-5897521)
- 2025-02-18 13:00 UTC [Conference Announcement] [Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival](https://www.quantisnow.com/insight/kiromic-biopharma-reports-patient-4-in-deltacel-01-clinical-trial-reaches-5892956)
- 2025-02-14 21:14 UTC [SEC Form 10-K] [SEC Form 10-K filed by Kiromic BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-kiromic-biopharma-inc-5890723)
- 2025-02-03 21:11 UTC [SEC Form 8-K] [Amendment: Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-5867360)
- 2025-02-03 16:10 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5866850)
- 2025-01-21 13:00 UTC [Conference Announcement] [Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01](https://www.quantisnow.com/insight/kiromic-biopharma-reports-tumor-volume-decrease-in-two-patients-enrolled-5851205)
- 2025-01-17 22:30 UTC [SEC Form S-1] [SEC Form S-1 filed by Kiromic BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-kiromic-biopharma-inc-5850452)
- 2024-12-12 13:00 UTC [Conference Announcement] [Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01](https://www.quantisnow.com/insight/kiromic-biopharma-reports-32-decrease-in-tumor-volume-eight-months-5810460)
- 2024-12-11 21:32 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5809598)
- 2024-12-03 16:02 UTC [Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation](https://www.quantisnow.com/insight/kiromic-biopharma-announces-settlement-of-previously-disclosed-sec-investigation-5797561)
- 2024-11-08 19:51 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kiromic BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kiromic-biopharma-inc-5762200)
- 2024-11-05 00:38 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Kiromic BioPharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-kiromic-biopharma-inc-5751833)
- 2024-11-04 21:32 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5751287)
- 2024-10-08 12:00 UTC [Conference Announcement] [Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01](https://www.quantisnow.com/insight/kiromic-biopharma-reports-favorable-ongoing-clinical-results-from-fourth-and-5719148)
- 2024-10-01 12:00 UTC [Conference Announcement] [Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial](https://www.quantisnow.com/insight/kiromic-biopharma-reports-favorable-10-month-follow-up-results-for-the-first-5709495)
- 2024-09-30 20:29 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5708613)
- 2024-09-19 20:30 UTC [Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial](https://www.quantisnow.com/insight/kiromic-biopharma-activates-the-university-of-arizona-cancer-center-as-5699780)
- 2024-09-19 12:00 UTC [Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation](https://www.quantisnow.com/insight/kiromic-biopharma-advances-deltacel-01-into-expansion-phase-following-safety-monitoring-5699074)
- 2024-08-26 22:44 UTC [Insider Buy] [Chief Executive Officer Bersani Pietro bought $7,407 worth of shares (3,488 units at $2.12), increasing direct ownership by 3% to 142,333 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-bersani-pietro-bought-7407-worth-of-shares-5672374)
- 2024-08-21 20:29 UTC [Insider Buy] [Chief Financial Officer Hungerford Brian bought $8,802 worth of shares (4,000 units at $2.20), increasing direct ownership by 7% to 64,933 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-hungerford-brian-bought-8802-worth-of-shares-5667999)
- 2024-08-14 21:03 UTC [Insider Buy] [Chief Financial Officer Hungerford Brian bought $3,500 worth of shares (2,000 units at $1.75), increasing direct ownership by 3% to 60,933 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-hungerford-brian-bought-3500-worth-of-shares-5659908)
- 2024-08-14 12:00 UTC [Kiromic BioPharma's Deltacel Receives FDA Fast Track Designation](https://www.quantisnow.com/insight/kiromic-biopharmas-deltacel-receives-fda-fast-track-designation-5658264)
- 2024-08-09 19:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Kiromic BioPharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-kiromic-biopharma-inc-5652597)
- 2024-08-09 12:00 UTC [Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial](https://www.quantisnow.com/insight/kiromic-biopharma-provides-update-on-part-1-of-the-deltacel-01-5652135)
- 2024-08-05 20:33 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5642596)
- 2024-08-01 12:00 UTC [Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01](https://www.quantisnow.com/insight/kiromic-biopharma-reports-20-tumor-size-reduction-at-eight-months-5637063)
- 2024-07-18 12:00 UTC [Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase](https://www.quantisnow.com/insight/kiromic-biopharma-to-advance-deltacel-01-clinical-trial-to-part-2-5614597)
- 2024-07-10 00:01 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5600626)
- 2024-06-28 20:30 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-submission-of-matters-5584132)
- 2024-06-27 21:21 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5581977)
- 2024-06-20 12:00 UTC [Conference Announcement] [Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial](https://www.quantisnow.com/insight/kiromic-biopharma-provides-updates-on-its-deltacel-01-clinical-trial-5567172)
- 2024-06-13 22:32 UTC [Insider Buy] [Director Misajon Pamela bought $5,288 worth of shares (1,610 units at $3.28), increasing direct ownership by 6% to 28,811 units (SEC Form 4)](https://www.quantisnow.com/insight/director-misajon-pamela-bought-5288-worth-of-shares-1610-units-5557296)
- 2024-06-13 20:30 UTC [Insider Buy] [CFO Hungerford Brian bought $2,600 worth of shares (1,000 units at $2.60), increasing direct ownership by 2% to 58,933 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-hungerford-brian-bought-2600-worth-of-shares-1000-units-5556723)
- 2024-06-12 20:37 UTC [Insider Buy] [Director Nagel Michael bought $3,330 worth of shares (1,000 units at $3.33), increasing direct ownership by 2% to 43,296 units (SEC Form 4)](https://www.quantisnow.com/insight/director-nagel-michael-bought-3330-worth-of-shares-1000-units-5554129)
- 2024-06-12 20:36 UTC [Insider Buy] [Director Misajon Pamela bought $4,984 worth of shares (1,701 units at $2.93), increasing direct ownership by 7% to 27,201 units (SEC Form 4)](https://www.quantisnow.com/insight/director-misajon-pamela-bought-4984-worth-of-shares-1701-units-5554125)
- 2024-06-12 20:36 UTC [Insider Buy] [CFO Hungerford Brian bought $3,180 worth of shares (1,000 units at $3.18), increasing direct ownership by 2% to 57,933 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-hungerford-brian-bought-3180-worth-of-shares-1000-units-5554118)
- 2024-06-12 20:35 UTC [Insider Buy] [CEO Bersani Pietro bought $19,530 worth of shares (6,000 units at $3.25), increasing direct ownership by 5% to 138,845 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-bersani-pietro-bought-19530-worth-of-shares-6000-units-5554111)
- 2024-06-07 20:30 UTC [SEC Form 8-K] [Kiromic BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/kiromic-biopharma-inc-filed-sec-form-8-k-entry-into-a-5545838)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KRBP
- Earnings history: https://www.quantisnow.com/earnings/KRBP
- Dividend history: https://www.quantisnow.com/dividends/KRBP
- Insider transactions: https://www.quantisnow.com/insiders/KRBP
- Options chain: https://www.quantisnow.com/options/KRBP
- SEC 8-K filings only: https://www.quantisnow.com/company/KRBP/8-k
- RSS and alerts for KRBP: https://www.quantisnow.com/docs/rss-feeds.md
